A Phase 3 trial of a candidate vaccine to prevent infection from the human immunodeficiency virus (HIV) has failed and the clinical trial is being discontinued, Janssen Pharmaceutical Companies announced on 18 January. The decision was taken on the advice of the study’s independent Data and Safety Monitoring Board which concluded that the vaccine was not effective in preventing HIV infection compared with a placebo. No safety issues related to the vaccine were identified.
